Has Loukas Boutis, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,795 in general payments to Loukas Boutis, MD across 74 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Loukas Boutis, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Loukas Boutis, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Loukas Boutis, MD

Cardiovascular Disease · Manhasset, NYNPI 1255535241

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,090 of the $4,795 with a category attached, or 85.3%. 11 manufacturers reported payments, led by Boston Scientific at 30.9% of the total.

$4,795in general payments, 2019–2025

Across 74 payments — averaging $64.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$1K
Medtronic$1K
Abbott$508
Edwards Lifesciences$420
Cardiovascular Systems Inc.$417
Shockwave Medical, Inc$309
plus $346 from 5 others

$777,410in research payments, 2019–2025

Across 25 payments — averaging $31,096 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$767K
Boston Scientific$11K

What the payments were for

Travel & lodging$70515%
Food & beverage$4,09085%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	12	$1,481
Medtronic(2 entities)	22	$1,313
Abbott	4	$508
Edwards Lifesciences	3	$420
Cardiovascular Systems Inc.	20	$417
Shockwave Medical, Inc	2	$309
Abiomed	3	$173
Penumbra, Inc.	5	$88
Cardiva Medical, Inc.	1	$33
Heartflow, Inc.	1	$28
W. L. Gore & Associates, Inc.	1	$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

GENERAL - THERAPIES$677
COREVALVE EVOLUT R$517
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$309
SYMPLICITY G3$243
Resolute$227
Diamondback Peripheral$176
Diamondback Coronary$176
MitraClip System$174
NAVITOR$160
General - Balloon Catheters$149
WATCHMAN Access System$145
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$139
Edwards SAPIEN 3 Transcatheter Heart Valve$138
GENERAL - STRUCTURAL HEART$126
SYNERGY$120
HawkOne$110
GENERAL - STENTS$103

How this compares

$4,795 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York →

Medicare billing

Part B allowed, 2024

$264,592

Medicare patients

578

Services billed

2,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	176	$243,416
EntrestoSacubitril/Valsartan	86	$106,630
XareltoRivaroxaban	75	$82,674
Repatha SureclickEvolocumab	129	$78,488
JardianceEmpagliflozin	15	$25,601
Repatha SyringeEvolocumab	49	$24,514
MultaqDronedarone Hcl	14	$21,137
BrilintaTicagrelor	13	$16,477
Praluent PenAlirocumab	27	$16,001
Metoprolol Succinate	412	$6,502
Atorvastatin Calcium	334	$3,827
Ranolazine ErRanolazine	14	$2,972
Rosuvastatin Calcium	224	$2,820
ClopidogrelClopidogrel Bisulfate	219	$2,525
Nebivolol Hcl	26	$2,287

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Manhasset

Bruce RutkinManhasset$267K
Roger HajjarNew York$5.2M
Szilard VorosStony Brook$3.7M
Gregg StoneNew York$2M
Augustin DelagoAlbany$1.8M
Philippe GenereuxNew York$1.3M
Adam RosenbluthNew York$1.1M
Luigi di BiaseBronx$978K
Vijay IyerAmherst$855K
Megha PrasadNew York$813K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →